Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Clinical trial NCT01742988 · COMPLETED

Trial details

NCT number: NCT01742988
Sponsor: Curis, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma Relapsed Lymphoma Refractory Lymphoma Relapsed and/or Refractory Lymphoma Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Double-hit Lymphoma (DHL)Triple-hit Lymphoma (THL)Double-expressor Lymphoma (DEL)High-grade B-cell Lymphoma (HGBL)

Start date: 2012-12-01
Primary completion: 2020-10-09
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.